Stan Riddell MD., Fred Hutchinson Cancer Research Center (IMAGE)
Caption
T-cell therapy, a form of immunotherapy that uses a patient's own immune cells to attack their cancer, has been making waves recently. The "living" therapy involves engineering the patient's T cells in the laboratory to carry new proteins that guide the immune cells directly to tumor cells, allowing the engineered T cells to attack and kill the cancer. Now, a group of researchers led by Fred Hutchinson Cancer Research Center immunotherapy researcher Dr. Stanley Riddell has devised a new approach that could speed and improve this process, using a special, small protein tag that can be used to purify and track the T cells once they have been engineered in the laboratory.
Credit
Fred Hutch News Service
Usage Restrictions
Per Embargo
License
Licensed content